January 30, 2024

Immune Checkpoint Inhibitor–Based Therapy May Have Comparative Efficacy in Black and White Patients With Metastatic Renal Cell Carcinoma

In a study presented at the 2024 ASCO Genitourinary Cancers Symposium, investigators compared the efficacy of immune checkpoint inhibitor–based therapies vs sunitinib as front-line treatment in Black ...

The ASCO Post

November 22, 2023

Adjuvant Everolimus Improves Recurrence-Free Survival in Very High–Risk Renal Cell Carcinoma

A secondary analysis from the phase III SWOG S0931 EVEREST trial found that adjuvant everolimus given to patients with clear cell renal cell carcinoma at very high risk of recurrence after nephrectom...

The ASCO Post

May 09, 2024

Belzutifan in Previously Treated Advanced Renal Cell Carcinoma

On December 14, 2023, a new treatment for unresectable locally advanced or metastatic clear cell renal cell carcinoma was approved, showing favorable outcomes compared to existing therapy.

The ASCO Post

December 27, 2023

FDA Approves Belzutifan for Advanced Renal Cell Carcinoma

On December 14, the FDA approved an HIF-2α inhibitor for patients with advanced RCC following treatment with a PD-1 or PD-L1 inhibitor and a VEGF TKI.

The ASCO Post

June 23, 2023

In Case You Missed It: Brief Highlights From Studies Presented During AACR 2023

Presented here are some highlights of preliminary studies presented at the 2023 American Association for Cancer Research (AACR) Annual Meeting. These presentations provide signals for the utility of a...

The ASCO Post

August 18, 2023

Addition of Atezolizumab to Cabozantinib in Renal Cell Carcinoma Progressing During or After Prior Immune Checkpoint Inhibition

In the phase III CONTACT-03 trial reported in The Lancet, Sumanta K. Pal, MD, FASCO, and colleagues found that the addition of atezolizumab to cabozantinib did not improve outcomes in patients with re...

The ASCO Post

March 16, 2023

Extended Follow-up Supports First-Line Use of Nivolumab Plus Cabozantinib in Advanced Renal Cell Carcinoma

The 3-year follow-up of the phase III CheckMate 9ER trial demonstrates superior outcomes with the combination of nivolumab plus cabozantinib vs the former standard-of-care sunitinib as first-line trea...

The ASCO Post

July 14, 2023

Novel Radiotracer May Accurately Detect and Differentiate Renal Cell Carcinomas

The new positron-emission tomography tracer zirconium (Zr)-89–DFO-girentuximab may accurately identify patients with clear cell renal cell carcinoma and differentiate the disease from other types of r...

The ASCO Post

November 13, 2023

Belzutifan Improves Outcomes for Pretreated Patients With Clear Cell Renal Cell Carcinoma Compared to Everolimus

How did treatment with a HIF-2α inhibitor compare against everolimus therapy in pretreated patients with advanced clear cell RCC? Investigators from the phase III LITESPARK-005 trial presented their f...

The ASCO Post